BEST UNLIMITED TURBO LONG CERTIFICATE - ELI LILLY & CO | Market Closed - Euronext Paris 17:25:25 22/05/2024 BST | ||
| 3.27 EUR | -2.53% |
|
| Current month | +10.96% | ||
| 1 month | +51.40% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 22/05/24 | 3.27 | -2.53% |
| 21/05/24 | 3.355 | +15.29% |
| 20/05/24 | 2.91 | +7.38% |
| 17/05/24 | 2.71 | -4.58% |
| 16/05/24 | 2.84 | -1.05% |
Real-time Euronext Paris
Last update May 22, 2024 at 05:20 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| 7A85S | |
| ISIN | DE000SU78300 |
| Date issued | 13/02/2024 |
| Strike | 626.4 $ |
| Maturity | Unlimited |
| Parity | 50 : 1 |
| Emission price | 2.47 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.515 € |
|---|---|
| Lowest since issue | 1.86 € |
| Spread | 0.02 € |
| Spread % | 0.61% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
803.2
USD
Average target price
850.4
USD
Spread / Average Target
+5.88%
- Stock Market
- Certificates
- 7A85S Certificat
